secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001104659-24-090153
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata appoints David House as SVP, Finance and principal financial officer
---------------------------------------------------------------------------

- David House appointed SVP, Finance and principal financial officer, effective Aug. 16, 2024.
- Base salary $350,000; target bonus 40% of base; option for 75,000 shares vesting over 4 years.
- Previously Corporate Controller and VP of Accounting at ZO Skin Health (acquired by Blackstone).
- Prior principal financial officer Richard Rychlik will remain as Corporate Controller.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924090153/0001104659-24-090153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924090153/tm2421653d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-090153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer